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ABSTRACT
BACKGROUND: Pain is the most common ailment around the world, according to the
American Academy of Pain Medicine; 100 million Americans suffer with chronic pain,
which is more than any other main disorder and is described by more than 60% as
impacted their overall enjoyment of life (AAPA). The ketogenic diet (KD) is a high fat,
low carbohydrate dietary regimen, which is described to decrease neuronal excitation,
increase ketone bodies and ATP levels, while lowering glucose and proinflammatory
cytokines. The KD is an effective therapy for epilepsy; a disorder that arises from either
lowered inhibition or increased excitation, similar to pain. The goal of the current study
is to establish whether the KD is effective in lowering inflammatory pain in a rat.
METHODS: We investigated whether a strict KD decreases inflammatory pain in adult
male rats. Rats were maintained on either the KD or a standard diet for two to four
weeks. We obtained both physiological measure and behavioral measures before and
after being injected in the right hind paw with heat-killed tuberculosis bacteria (CFA) to
cause inflammation. Physiological measures included weight, paw volume, paw
weight, blood ketone and blood glucose levels. Tactile sensitivity and spontaneous pain
was used to assess behavioral pain.
RESULTS: Ketones were increased in rats after the KD. Our results indicate that the KD
may alleviate pain, as there were significant changes indicating lowered swelling from
the right paw weight. Paw volume indicated a trend leading us to believe that there
may be significance if there were more rats. This was similarly seen in the tactile
sensitivity, where there was a trend of KD having lowered pain at 4 hours post-injection
compared to CD. Spontaneous pain and myeloperoxidase had no significant changes
between the KD and CD groups.
CONCLUSION: The data suggest that KD may alleviate pain as there is a lower
inflammatory swelling and a trend towards decreased pain sensitivity. Future research
will aim to elucidate whether there is an effect of the KD on inflammatory pain by using
lower amounts of CFA and earlier spontaneous pain testing.
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INTRODUCTION
PAIN
Background
Pain can be described as a sensory and/or emotional experience that results from
physical damage such as tissue injury or nonphysical damage such as emotional pain.
Pain is often considered a symptom of another illness and, while often true, pain has a
variety of causes and is not fully understood mechanistically. Pain has been classified
into various categories but most frequently for clinical assessment and treatment it is
separated into: nociceptive, neuropathic, and inflammatory pain (Pain Management, 2010).
This classification illustrates the massive scope the term pain encompasses. These three
categories, defined in detail below, are defined by the location of the area affected.
Researchers believe that there is not one mechanism, which encompasses all three types
of pain. Rather it is commonly believed that there is a combination of several
mechanisms that cause pain, as it is well known that inflammatory mechanisms are
involved in neuropathic pain.
Pain is the most common ailment around the world, a recent study states that
more than 1.5 billion people suffer from chronic pain while 3-4.5% suffer from
neuropathic pain (Global Industry Analysts, 2011). Throughout history there has been a
multitude of methods to treat and understand pain, however there has still been no
treatment to successfully treat all types of pain. It is necessary thus to find a safe and
effective treatment to alleviate individuals suffering with unrelenting or undertreated
pain.
7

Treatment and Prevalence
Pain embodies a wide range of conditions including arthritis, migraines, spinal
injuries, cancer, neuropathic pain, and others.
According to the American Academy of Pain Medicine, 100 million Americans
suffer with chronic pain, more than any other main disorder. The survey study on
chronic sufferers revealed that roughly 60% reported that the chronic pain impacted
their overall enjoyment of life (American Pain Foundation, 2006). A survey conducted
by the American Pain Foundation (2006) on approximately 300 chronic pain sufferers
found that more than half felt they had no control over their pain. Individuals with
severe pain have trouble concentrating, they report that their energy level is impacted,
and many report an inability to get restful sleep (Niels Becker et al., 1997). These
individuals run a risk of developing various comorbidities, may not receive pain relief
from medication, and due to cost of medication may develop a financial burden. In the
United States the total annual cost of health care due to pain was between $560-635
billion in 2010 (National Academies Press, 2011).
Chronic pain is frequently comorbid with other psychiatric diseases most often
with panic disorder, post-traumatic stress disorder and depression (McWilliams, Cox &
Enns, 2003). Treatment for chronic pain typically includes NSAIDs, opioids,
antiepileptic drugs, and antidepressants. The use of over-the-counter and prescription
drugs for both acute and chronic pain is very common in Western culture and yet it is
less than ideal as it has several downfalls: it can cause tolerance, dependence and
addiction, and it does not always provide the relief necessary to live a normal life.
Prescription drug abuse has increased substantially from 1998 to 2008, and is
8

considered to be a major contributor to drug deaths (SAMHSA, 2010; CDC, 2010).
Individuals may not respond positively to pain medicine due to genetic mutations that
alter their drug metabolism or may suffer from other issues such as addiction or
tolerance.
There is a necessity for more research to understand pain. Recent research has
linked the ketogenic diet as providing analgesic effects with little or no side effects. Pain
affects individuals’ in physical, psychological and economical. Finding an effective and
efficient way to manage pain is vital to decrease the burden it places on families and
society.

Pain Etiology
The pathophysiology of pain has not been completely elucidated, however it is
hypothesized that pain is linked to over-excited nerves. Over-excited nerves can arise as
a result of glutamate-induced excitotoxicity, increased glutamatergic receptors, or
decreased GABA or GABA receptors. Individuals with psychological illnesses such as
major depression, somatization disorder and hypochondriasis are much more likely to
develop a chronic pain disorder. This connection suggests that there is a common factor
among these disorders heightening the probability of comorbidity with pain.
Pain typically arises from injury, inflammation and/or disease and is
perpetuated by the interplay of stress responses, deregulated injury signaling and
negative emotions. Pain can be beneficial when it acts as a warning but can cause a
deleterious impact when it is extended. There are multiple types of pain each with
commonalities and differences in the way they are derived and understood.
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As mentioned above the three common types of pain are nociceptive, neuropathic
and inflammatory. Here each is discussed briefly related to the etiology of pain.
Nociceptive pain results from exposure to external stimuli, these neurons express a
multitude of ion channels. Changes in these channels can affect the processing of pain.
Neuropathic pain is a result of tissue damage or disease, which can damage nerve fibers
causing pain. Sensory processing abnormality is often altered and individuals may
report hyperalgesia, increased pain sensitivity, or allodynia, a condition where nonpainful stimuli cause pain. Inflammatory pain involves the interplay between the
immune system and the central nervous system.
Injury, inflammation and disease can all alter neuronal structure by altering
neurotransmitters (inter-neuronal chemical messenger), receptors (a protein which in
the presence of specific neurotransmitters transmits a signal to a neuron), ion channels
(protein which allows for an influx or efflux of ions in the cell), and connections
(number of synaptic terminals) (Stucky, Gold & Zhang, 2001). It is hypothesized that
pain is either a result from increased excitatory or decreased inhibitory activity
(discussed below; Stucky, Gold & Zhang, 2001).

Inflammatory Pain
This study will focus on inflammatory pain and thus the rest of this section is
dedicated to the etiology of inflammatory pain. Inflammatory pain can result from both
endogenous and exogenous stressors. This change in activity alters the release of
various mediators including proinflammatory cytokines (IL-1-alpha, IL-1-beta, IL-6 and
TNF-alpha), chemokines, reactive oxygen species, vasoactive amines, lipids, ATP, acid,
and other factors (Focus on Pain, 2014). These regulators are typically released by
10

infiltrating leukocytes, vascular endothelial cells, or tissue resident mast cells (Focus on
Pain, 2014).
Sensory information arising from an inflammation typically activates afferent
neurons; this signal is relayed to the thalamus and brainstem (Kidd & Urban, 2001). In
the beginning stages of inflammation, studies have shown that prostaglandins and
bradykinin alter the sensitivity of receptors and reduce the excitatory threshold of
neurons (Dray, 1995). Long-term changes due to inflammation occur via cytokines and
growth factors causing transcriptional changes such as increasing receptors, ion
channels and/or neurotransmitters (Woolf & Costigan, 1999). High stimulus intensity
due to tissue damage induces substance P, which increases NMDA receptors and is
linked to higher activation via glutamate (Kidd & Urban, 2001). Thus, it is believed that
the underlying principal in pain is that the threshold for excitation is lowered,
producing more neuronal firing. Furthermore, substance P is secreted by nerves and
inflammatory cells and ultimately has been shown to have proinflammatory effects in
immune and epithelial cells (O’Connor et al., 2004).
Inflammatory pain is typically manifested by pain, heat, redness and swelling
(Maroon, Bost & Maroon, 2010). Pain is considered to arise most frequently from
inflammation, which is the type of pain we focus on in this thesis. Current
pharmacological intervention for inflammatory pain consists of non-steroidal antiinflammatory drug (NSAID), which are able to interfere with the inflammatory cascade
through inhibiting the production of prostaglandin (Talalay & Talalay, 2001). However,
NSAIDs medication has significant side effects and finding alternatives to reducing
pain and inflammation would be highly beneficial for many individuals. It has long
been known that fasting is anti-inflammatory, however, fasting can be extremely hard
11

and potentially dangerous for individuals to adhere to (Shibolet et al., 2002). The
ketogenic diet is a dietary regimen, which has been found to mimic fasting and is
suspected to help reduce pain and inflammation, which is further discussed below.

KETOGENIC DIET
Background
The ketogenic diet (KD) is a high fat, adequate protein, low carbohydrate
metabolic therapy that has been used to effectively treat epilepsy (Danial et al., 2013).
The KD was first recognized by the American Medical Association in 1921 in which Dr.
Rawle Geyelin presented the story of Dr. H.W. Conklin who treated his epileptic
patients with intermittent starvation and found cure rates up to 90% (Bailey, Pfeifer &
Thiele, 2004). Wilder and Winter at the Mayo Clinic were the first to suggest that the
effects of altering metabolism may be a result from the presence of ketone bodies and
proposed a diet with a higher fat and lower carbohydrate content (Bailey, Pfeifer &
Thiele, 2004). The KD mimics the fasting diet originally found to alleviate epileptic
seizures. This dietary regimen has since proven to successfully lower seizure rates in
both children and adults (Freeman, Kossoff, & Hartman, 2007). However, in the 1940s
anticonvulsants were introduced, and the popularity of the KD fell out of favor. The KD
was difficult to maintain compared to pharmaceutical interventions such as
anticonvulsants. Despite challenges in implementing the KD it has remained a powerful
treatment for epilepsy even when anticonvulsants fail. Recent studies suggest that the
KD may be effective in alleviating both psychiatric and physiological diseases. Research
on the KD is still limited, and a large gap remains on understanding the mechanism of
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action. However, drugs that treat epilepsy are often prescribed for pain, suggesting that
epilepsy and pain may share molecular elements.

Biochemical Pathway of the Ketogenic Diet
The KD reduces carbohydrate consumption while increasing fat intake
ultimately
metabolism

lowering
and

glucose

increasing

fat

metabolism. The entire mechanism of
the KD is still unknown, but it is well

known that KD allows for the

Figure 1. Ketone Body Synthesis from Acetyl-CoA

breakdown of fatty acids in the liver which is the exported to extra-hepatic sites
including the brain. The mitochondria in the liver converts β-oxidation-derived acetylCoA to ketones via mitochondrial thiolase, HMG-CoA synthase, and HMG-CoA lyase
(Danial et al., 2013). The ketone bodies (acetone, acetoacetate, β-hydroxybutyrate)
provide an alternative energy source (fig.1) (Danial et al., 2013).
The formation of ketone bodies occurs naturally at a slow level to provide energy
to certain organs (particularly the brain) or in fasting or exercise. Ketosis occurs when
glucose levels are low, glycogen levels are depleted and thus fatty acids are
metabolized. Fatty acids are β-oxidized into acetyl-CoA, which would typically proceed
to the tricarboxylic acid (TCA) cycle and would in turn drive the electron transport
chain for ATP synthesis. The KD lowers glucose intermediates such as oxaloacetate
causing fatty acid levels to exceed the metabolic capacity of the TCA cycle. The
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increased level of acetyl-CoA promotes the formation of ketone bodies, noted above are
water-soluble molecules that can be used as an energy source throughout the body,
including the brain (Masino & Rho, 2012). Ketone bodies are more efficient at making
ATP than glucose. Veech (2004) describes that due to a higher heat of combustion in Dβ-hydroxybutyrate there is a 28% increase in hydraulic efficiency compared to pyruvate,
the end product of glycolysis. Ketones can be synthesized to produce fatty acids in the
brain, which provide essential building blocks for biosynthesis of cell membranes and
other lipids (Danial et al., 2013). Mechanisms of how the KD is thought to affect the
body are described in a later section.

Dietary Regimen
The KD is a strict dietary regimen that must be maintained to elicit therapeutic
benefits. The “classic” KD is typically described as a ratio of 4:1 of fats to carbohydrates
+ to protein (Zupec-Kania & Spellman, 2008). Ketosis is typically reached after 72 hours
on the diet and when glucose levels are between 55-75 mg/dL and ketone levels range
between 4-10 mmol (Zupec-Kania & Spellman, 2008). The “classic” KD uses long-chain
triglygerides (LCT), which are 12-18 carbons in length and the predominant fat in the
American diet (Bach, Frey & Lutz, 1989). A meal on the “classic” KD may consist of
broccoli cooked in butter and ground beef cooked in a cream sauce. The “classic” KD
has a very high fat content and can be difficult to adhere to.
The modified KD was introduced as a more palatable alternative to the “classic’
KD. The modified KD uses medium-chain triglycerides (MCT), which are composed of
6 to 10 carbons (Bach, Frey & Lutz, 1989). MCTs are hydrolyzed more efficiently in the
body than LCTs, producing more ketones per calorie (Kossoff, Zupec-Kania & Rho,
14

2009). MCTs when metabolized to fatty acids are able to cross into the mitochondrial
membrane without the use of a transporter, and thus more quickly converted to fuel
(Bach, Frey & Lutz, 1989). The modified KD allows for more proteins and carbohydrates
ultimately making it more palatable: a typical meal may be brown rice, a salad with
vegetables, and chicken cooked in oil.
Coconut oil is an inexpensive MCT that has been receiving a lot of attention for
its multitude of beneficial effects. Furthermore, MCTs have been speculated at
enhancing the immune system (Bach, Frey & Lutz, 1989). Kono and colleagues (2000)
found that MCTs prevented alcohol-induced liver injury in rats by inhibiting reactive
oxygen species and TNF-α. TNF-α is a pro-inflammatory cytokine. Due to reduced fat
and increased food choice and variety the modified KD is a more palatable dietary
regimen that has been found to be just as affective as the “classical” KD.
Dietary treatments such as the KD have long been used as a strategy to combat
various clinical conditions. The KD is predominantly used as a treatment for epilepsy,
however evidence is growing that the KD could be effective in treating a wide range of
diseases and disorders (table 1) (Kossoff, Zupec-Kania & Rho, 2009).

Table 1. Uses of the Ketogenic Diets Published in Literature
(Adapted from Barañano & Hartman, 2008)
-

Human Studies
Seizures (epilepsy)
Metabolic Defects (PDH and PFK
deficency, and glycogenosis type V)
Reduced Astrocytomas
Neurological disorders (AD & PD)
Autism
Migraines and Narcolepsy
Glioblastoma multiforme

-

Animal Studies
Tumors Reduction (gliomas,
prostate cancer, gastric cancer)
Protects against Truma and
ischemia
Neurological disorders (AD & PD)
ALS
Depression
Autism

Table 1. The table above outlines different disorders that have been studied on the KD
in either a human or rodent subjects. The italicized have little concrete research or
clinical studies in progress.
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The worldwide use of the KD has increased with now 73 academic centers in 41
countries advocating it as a therapeutic approach to various illnesses (Kossoff &
McGrogan, 2005).

Ketogenic Diet mechanism of action
The mechanism of action in the KD is still poorly understood, but it has been
linked to reduced neuronal excitability, described below. It is unknown whether the
reduced neuronal excitability is caused directly by an increase in ketone bodies and/or
a decrease in glucose or the result of another mechanism (Ruskin & Masino, 2012). The
potential mechanisms are outlined below (Table 2). There is likely a complex interplay
of

different

networks

including

the

biochemical

and

physiological

systems

consequently it may be a combination of more than one mechanism that provides some
of the alleviating affects we have seen in the KD. Once this mechanism is understood
there are opportunities of easily accessing the vast benefits of the KD without adhering
to the constraints of the diet.

Table 2. KD Hypothesis for Mechanisms of Action
•
•
•
•
•

Ketone Hypothesis (Glucose Hypothesis)
Adenosine Theory
Anti-inflammatory and Lowered Reactive Oxygen Species
Metabolic hypothesis
Amino Acid Hypothesis

Table 2. The table above outlines the five most common KD hypotheses.

The KD can decrease neuronal excitation, reduce reactive oxygen species,
increase adenosine, produce hypoglycemia, alter inflammatory cytokines and
16

reduce swelling after experimental inflammation (Merry, 2004; Maalouf et al.,
2009). The following section elaborates on these mechanisms and how they may
underly effects of the KD.
•

The ketone hypothesis predicts that the ketone bodies have a direct
anticonvulsant effect (Nylen, Likhodii, & Burnham, 2009). Ketone bodies
form in excess under low carbohydrate and increased glucose, thus this
hypothesis is closely linked to lowered glucose intake from the KD.
Acetone, a ketone body, has been shown to have anticonvulsant effects
however the specific mechanism is unknown, it is speculated to act
through voltage-gated potassium channels (Masino & Rho, 2012). Juge
and his colleagues (2010) recently discovered a link between ketone bodies
and neuronal excitability. They determined that acetoacetate, a ketone
body, inhibits vesicular glutamate transporters (Juge et al., 2010). Juge and
colleagues (2010) found that ketone bodies compete with chloride ions,
which act as an allosteric activator on the vesicular-glutamate transporter.
These transporters are required for the storage of the excitatory
neurotransmitter glutamate in vesicles, for later synaptic release. Lowered
synaptic glutamate means lowered neuronal excitability, thereby lowering
the

occurrence

of

seizures.

Furthermore,

both

acetone

and

β-

hydroxybutyric acid enhance GABA receptor function, illustrating the
there is increased inhibition (Yang et al., 2007). Individuals with
depression have too much glutamate in their synapses thus the glucose
hypothesis offers a potential therapeutic approach for depression; this link
is being researched further (Sanacora, Treccani & Popoli, 2012).
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•

The adenosine hypothesis predicts that the KD increases adenosine, which
inhibits neuronal excitability through adenosine A1 receptors (A1Rs)
(Masino et al. 2009). Adenosine is a neuromodulatory purine; it has been
shown in vivo and in vitro that KD feeding reduces seizure and seizure like
activity via A1Rs (i.e. KD effects were blocked by pharmacological or
genetic A1R inactivation) (Masino et al. 2011; Kawamura et al., 2014). The
in vitro studies demonstrated that KD-related adenosine was derived from
the break down of ATP (core of the ATP molecule) (Masino et al. 2011;
Kawamura et al., 2014). This ATP was released from intracellular stores
from pannexin channels (Masino et al. 2011; Kawamura et al., 2014). The
KD is known to increase ATP levels in the brain (Pan et al. 1999).

•

A low carbohydrate high fat diet was shown to significantly reduce
proinflammatory cytokines and reactive oxygen species. Proinflammatory
cytokines including TNF-α, IL-6, MCP-1, E-selectin, I-CAM, and PAI-1
were reduced on a KD compared to a low fat diet (Forsythe et al., 2007).
Lowering proinflammatory cytokines is beneficial in a vast number of
diseases and disorders. Ruskin et al. (2009) found that the KD reduces
experimental inflammation as measured by paw swelling and plasma
extravasation. A diet that forces fats to be metabolized reduces the amount
of superoxide produced from the electron transport chain, because the
beta-oxidation allows for the by-pass of the mechanism that converts
glucose to pyruvate (Veech, 2004). This would ultimately reduce the
reactive oxygen species throughout the body (Manninen, 2004). Reactive
18

oxygen species at high concentrations are detrimental to cells and cause
apoptosis, whereas evidence suggests reducing reactive oxygen species is
beneficial for the body and mind.
•

The metabolic hypothesis proposes that the KD is more efficient at
providing energy to the brain (Nylen, Likhodii, & Burnham, 2009). Ketone
bodies produce more ATP per unit than glucose (elevated ATP production
reactive oxygen species, which actually argues against the antiinflammatory hypothesis above). Furthermore Bough et al. (2006)
reported that the KD increases the number of mitochondria in a rat. Many
neurological disorders have dysfunctional mitochondria, and thus the KD,
which increases their number and efficiency, measured via electron
microscopy, with the extra energy from ketone bodies, is ultimately able
to improve metabolic function and provide therapeutic relief.

•

The fifth hypothesized mechanism is the amino acid theory, which
suggests that the KD modifies the balance of amino acid neurotransmitters
in the brain. When the brain changes from glucose to ketone body
metabolism the ratio of glutamate to GABA decreases, increasing
GABAergic inhibition.
Overall the KD is postulated to decrease neuronal excitation by increasing

ketone bodies and ATP levels and lowering glucose and proinflammatory
cytokines. The KD was also found to increase adenosine and GABA, both
inhibitory

neuromodulators,

and

decrease

glutamate,

an

excitatory

neuromodulator (Masino and Geiger, 2008; Omote et al., 2011; Juge et al., 2010).
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PROPOSED CONNECTION- Ketogenic Diet and Pain
As noted, the KD is thought to increase inhibition and/or decrease
excitation. The KD is an effective therapy for epilepsy; a disorder that arises from
either lowered inhibition or increased excitation, similar to pain. Studies suggest
that the KD can be used for pain relief and lowering inflammation. The following
evidence described below illustrates converging evidence of the likely effects of
the KD influencing pain and inflammation. Masino and Ruskin (2013) describe
four postulated mechanisms of the reasoning behind the therapeutic affects of
the KD and pain and inflammation (table 3).

Table 3. Ketogenic Diet, Pain and Inflammation: Postulated
Mechanisms (Masino & Ruskin, 2013)
1. Reduces excitatory and/or increases inhibitory mechanisms
2. Fewer reactive oxygen species has anti-inflammatory effects
3. Adenosine has anti-inflammatory effects
4. Reducing glycolytic metabolism is analgesic

Masino and Ruskin (2013) highlight studies relating high fat and low
carbohydrate diets to the perception and inflammation of pain; together these
studies suggest a link between these two areas, consistent with postulated
mechanisms. These are discussed in detail below.
•

Epilepsy and pain have been described as complex conditions that have
diverse underlying conditions but both seem to have overexcited nerves.
20

It is presumed that a treatment that can reduce the excitability of nerves
would be a good therapy for pain. Anticonvulsants drugs are often used
for neuropathic pain, further exemplifying that if the KD decreases
excitatory or increases inhibitory mechanisms in epilepsy then it could
produce the same affect in pain (Masino & Ruskin, 2013).
•

Reactive oxygen species are a major component of inflammation, and as
noted previously the KD reduces reactive oxygen species. Exogenous
ketones were shown to reduce reactive oxygen species both in vitro and in
vivo (Kim, Vallejo & Rho, 2010; Masino & Ruskin, 2013). Thus, a diet such
as the KD that alter the metabolism and creates increased levels of ketones
could be expected to reduce reactive oxygen species. Reactive oxygen
species are linked to numerous diseases and disorders, specifically
Wiseman and Halliwell (1996) describe that reactive oxygen species have
been increasingly linked to inflammatory disease as well as cancer. The
KD was found to reduce reactive oxygen species in the brain and
ultimately reduce inflammation in a model of multiple sclerosis and in
individuals with liver disease (Kim et al., 2012; Tendler et al., 2007).

•

Adenosine levels are increased on the KD and adenosine has long been
implicated in reducing inflammation and pain, by inhibiting neuronal
excitability through the A1Rs (Masino et al., 2009). Schmidt et al. (2009)
determined, that allopurinol, a non-selective adenosine-receptor that
increases adenosine levels induced anti-nociception.

•

Reducing glycolytic metabolism is hypothesized to be another mechanism
that provides a decrease in excitatory and/or increase in inhibitory
21

mechanisms. One study found that children on a MCT diet who had their
seizures under control when given an infusion of glucose their seizures
quickly returned (Huttenlocher, 1976). As discussed previously, pain is
related to overly excited neurons and thus if reducing glucose is inhibitory
it is expected to lower pain Furthermore when 2-deoxy-D-glucose, which
blocks glycolysis, was found to have anticonvulsant effects (Bodnar et al.,
1979).
The described mechanisms above suggest a link that should be further analyzed
between the KD and different types of pain. Our lab found that an acute model
of pain using thermal pain had an increased thermal pain sensitivity when on the
KD compared to control rats (Ruskin et al., 2013). These effects were reversed
once the KD rats were placed on the control diet (Ruskin et al., 2013).
Furthermore, our lab has studied the relationship between the KD and
inflammatory pain. One study used local inflammation into the hindpaw with
complete Freund’s adjuvant to examine swelling and plasma extravasation in
juvenile and adult rats (Masino & Ruskin, 2013). Juvenile rats had significantly
reduced levels of these two types of inflammation when on the KD; these results
were less but still significant in adults (Masino & Ruskin, 2013). Another study
on neuropathic pain used the antimitotic cancer drug in which rats were on the
KD prior to injection (Masino & Ruskin, 2013). The study found reduced
mechanical pain sensitivity on rats fed a strict 6:6:1 diet at the 8-day time point
(Masino & Ruskin, 2013). Another study by Piomelli and Sasso (2014) found that
an increasing number of lipid molecules are able to suppress the inflammatory
process, restore homeostasis in damaged tissue, and attenuate pain sensitivity by
22

regulating the peripheral nervous system. One study regarding pain and the KD
showed a strong trend towards the KD alleviating pain (Yancy et al., 2009). This
research suggests that there should be more research to determine whether a
strong relationship exists between different types of pain and the KD.
Overall pain is a prevalent and challenging disorder and there are many
individuals with unrelenting or unmet need for treatment of pain and
inflammation. The KD or a metabolic therapy would be a platform that
individuals all around the world could use to tackle their pain. Here we study
this intersection between these two fields of research and test the effects of a KD
on inflammatory pain.
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Thesis Overview and Hypothesis
The current study aims to test the hypothesis that a ketogenic diet will
reduce inflammatory pain. This study will help gather evidence whether the
ketogenic diet could be used as a therapy for individuals experiencing pain and
reducing inflammation. In the present study we use both behavioral and
inflammatory markers to analyze rats on a strict ketogenic diet versus rats on a
normal chow after they are injected with CFA (complete Freund’s adjuvant) in
their right hind paw to cause persistent inflammation.
We expect one of two scenarios: inflammation and inflammatory pain are
lowered or only inflammatory pain is lowered. If inflammation and
inflammatory pain were lowered on the ketogenic diet, it suggests that the
ketogenic

diet

reduces

inflammatory

pain

by

reducing

inflammation.

Alternatively, if the behavior indicates less pain but there is no significant change
in the inflammation, it would suggest this alleviation occurs through an antinociceptive mechanism.
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METHODS
Ethics Statement
Procedures were followed according to the NIH Guide for the Care and
Use of Laboratory Animals and were approved by the Animal Care and Use
Committee of Trinity College (A3869-01).

Animals and Method Overview
Male Sprague-Dawley rats were fed a standard chow diet until eight
weeks of age. Two to three rats were housed together in cages with water and
enrichment toys and kept on a 12 hr light-dark cycle. At eight weeks, half the rats
were switched onto a ketogenic diet (KD) (F3666; BioServ, Frenchtown, NJ) for
two or four weeks while the other half remained on a standard chow diet (SD).
The KD was a “classic” research formulation with a ketogenic ratio of 6:1. All
testing occurred two or four weeks after the dietary treatment, at which point
rats were 10-16 weeks of age.
Behavior tests consisted of spontaneous pain and tactile sensitivity and
were conducted before and after being injected in one hind paw with heat-killed
tuberculosis bacteria (CFA) that causes persistent inflammation. Weight and paw
volume were recorded throughout the dietary regimen. To verify ketosis glucose
and ketone levels are measured via tail blood and trunk blood respectively.
Upon sacrificing, two days post injection, blood and paws are collected to assess
inflammation. Rats were tested for five consecutive days in the order illustrated
(figure 2).
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Figure 2. Testing Schedule

Injection
Complete Freund’s Adjuvant (CFA)
All rats were subjected to 100uL of Complete Freund’s
Adjuvant (CFA) (thermo scientific) in the right hind paw to
induce the inflammation. CFA as mentioned previously is a
heat-killed

tuberculosis

bacteria

that

causes

persistent

inflammation.

Behavior Tests
Spontaneous Pain
Spontaneous pain was assessed using the spontaneous foot-lifting model.
Rats were habituated to the testing room for fifteen minutes prior to being placed
in an empty plastic cage for thirty minutes. The behavior test was recorded by a
video camera from underneath the cage. In a blinded analysis of the video each
hind paw was separately scored on a scale of 0-5 at 10, 15, 20 and 25 minutes for
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one minute.
Table 3. Scoring Paradigm for Spontaneous Pain
0

paw pressed normally on floor

1

paw rests
ventroflexed

2

only internal edge of paw pressed to floor

3

only heel pressed to floor, hind paw in
inverted position

4

whole paw is elevated

5

animal licks paw

lightly

on

floor,

toes

If there was locomotion or grooming at the time intervals listed then the time
scored was delayed. The spontaneous pain baseline measurement was at 48
hours prior to the CFA injection, and compared to the 24 hours post injection.
(Djouhri et al., 2006).
Tactile Sensitivity - Electrical
Nociceptive pain was quantified with an electrical measure of pressure
using the electronic von Frey (Almemo 2390-5, IITC). The device recorded the
maximum amount of pressure applied to each hind paw. This was repeated to
achieve two recordings, which were averaged.

Physiological Measures
Paw Displacement
Paw volume was measured prior to the CFA injection and at 48hours, just
prior to sacrifice. The paw volume was measured via water displacement using a
digital analytical balance (Mettler-Toledo) to determine the difference. Paw
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volume provides a measurement on the level of physical inflammation of the
paw.
Procedures at Sacrifice
Animals were sacrificed at 48 hours post CFA injection; the rats were
anesthetized by being exposed to isoflurane in a large glass container. The blood
glucose level was measured from tail blood by puncturing the tail with a
hypodermic needle, while ketone (beta-hydroxybutyrate) level was measured
from trunk blood after decapitation. The blood glucose and ketone levels were
analyzed using a Precision Xtra glucose/ketone meter strips (Abbott
Laboratories, Bedford, MA).
Trunk blood was collected and centrifuged to isolate the plasma and
frozen for later analysis on the inflammatory markers present. After sacrifice the
hind paws are amputated at the ankle joint. Paws are weighed on a digital
analytical balance (Mettler-Toledo). Hindpaw pads are dissected, frozen in liquid
nitrogen and crushed, and sonicated and repeatedly freeze/thawed to disrupt all
membranes. After centrifugation, supernatant was tested with an enzyme assay
for myeloperoxidase, an enzyme contained in neutrophils, the most common
type of leukocyte. The change of absorbance at 460nm was measured
spectophotometrically using the myeloperoxidase assay (Bradley et al. 1982). The
assay combined 0.1mL of the supernatant to 2.9mL of 50mM phosphate buffer,
pH 6.0, which contained 0.167 mg/mL o-dianisidine dihydrochloride and
0.0005% hydrogen peroxide (Bradley et al. 1982).
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Statistical Analysis
Three independent researchers with two of the three blinded to the diettreatment, scored the spontaneous pain. Statistical tests were performed using ttests and ANOVA, except in cases of non-normality where we used Wilcoxon
test. There were no statistical differences in paw weights between rats that
received two weeks of diet treatment to those who received four weeks, thus the
data was collapsed across these two groups. P<0.05 was considered significant.
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RESULTS
Rats underwent physiological measures (ketone and glucose levels, weight, and
leukocyte levels) as well as behavioral tests (tactile sensitivity and spontaneous
pain) to determine whether there was a difference in inflammatory pain between
KD and CD rats.

Physiological Results
Blood Analysis: β –hydroxybutyrate (ketone) & Glucose
Trunk blood was collected after decapitation and the β- hydroxybutyrate
levels were determined by Precision Xtra meters. β-hydroxybutyrate is a ketone
that indicates ketosis, and was found to be significantly higher in the KD group
compared to the CD group (Fig. 3A). The glucose levels between the two dietgroups had no significant difference (Fig. 3B). In prior studies and unpublished
data we have noticed that as rats age and the longer they adhere to the KD diet
the more comparable their glucose levels are to rats on a CD, often where they
difference is insignificant. This data highlights that the rats were in ketosis but
due to their age on diet onset there is often no change in glucose levels.
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A

B

Figure 3. (A) KD rats had significantly higher levels of β-hydroxybuturate than the CD
rats (p<0.001). (B) Glucose levels were not significantly altered in either group. (Male
rats, KD n=14; CD n=10 here and in every subsequent figure). Measurements were made
as described in methods.

Body Weight
Rats were weighed prior to the CFA injection, if there was a significant
difference between the body weights of the KD rats versus the CD rats that
would need to be taken into account for analysis. As depicted (Fig 4) there was
no significant difference between the body weights and thus the dose of CFA for
the rat size is consistent as is the paw volume.
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Figure 4. There was no significant difference in body weight of rats on the CD versus KD
diet at the time of CFA injection.

Paw Weight
Paws were obtained and weighed on the day of sacrifice, at 48 hours post
CFA injection. The KD right paws weighed significantly less than the CD (Fig. 5).
Left paws showed no significant difference between the two diet groups (Fig. 5).

Figure 5. Rats fed the KD had significantly higher right paw weights than CD (p<0.05).
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Paw Volume
Paw volume was measured using water displacement prior to CFA
injection, -24 hours, and post CFA injection, +48 hours. A trend indicating that
KD had less swollen paws is illustrated; however it did not quite reach
significance (Fig. 6A). There was no difference found between the left hind paw
of both diet groups suggesting that the difference is not due to size of the rats but
due to the KD treatment (Fig. 6B).

A

B

Figure 6. (A) KD rats had slightly lowered paw volume at 48 hours post CFA, the level
was not significant (p=0.055). (B) No difference in paw volume between KD and CD.

Leukocyte Levels
Leukocyte levels where measured using the myeloperoxidase assay. There was no
significant difference between the KD and CD in the right paw (fig. 7).
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Figure 7. No significant difference between the left and/or right paw between the KD
and CD groups in myeloperoxidase.

Behavioral Results
Tactile Sensitivity
Rats went through tests of tactile sensitivity before and after being injected
in the right hind paw with heat-killed tuberculosis bacteria to cause
inflammation. Tactile sensitivity using the electronic von Frey probe did not
differ between treatment groups before injection, but was strongly increased at 4
hours post-injection in both treatment groups. In the inflamed paw (right) there
was a lowered amount of pressure that the KD rats could withstand compared to
the CD rats. At 48 hr post-injection, sensitivity was no longer significant between
the KD and CD rats (fig 8A). There were no significant differences in tactile
sensitivity between the KD and CD in the left paw over the three time periods
(fig 8B).
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A

B

Figure 8. There was no significant difference in the tactile sensitivity prior to the
CFA injection. (A) At 4hr post CFA injection there was a trend for the KD rats to be
able to withstand more pressure to the inflamed paw (right) than the CD rats
(p=0.053). (B) Left paw showed no significant changes in response.

Spontaneous Pain
Spontaneous pain data illustrates an expected change between each
specific diet group and the pre and post CFA for the right paw (Fig 9A & 9B).
This significance illustrates that the CFA was causing a severe inflammation in
the right paw that debilitated the rats’ usual motor movement. However, there
was no significant difference across the groups for both prior and post CFA
injection (Fig. 9A & 9B). There was no significance between the left paw
treatments (Fig. 9C & 9D). The graphs illustrate the distribution of scores using a
box and whiskers plot. The top and bottom lines indicate the range of scores,
while the second line from the top and second line from the bottom illustrate the
first and third quartile of the data set. The average is the centerline in each box
plot.
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A

B

C

D

Figure 9. There was no significant difference in the spontaneous pain between KD
and CD in either the right paws (A & B) or between the left paws (C & D). (A) There
was a significant difference between pre-CFA and post-CFA in the right control paw
(p<0.01). (B) Similarly there was a significant difference seen between pre-CFA and
post-CFA in the right control paw (p<0.01). (C & D) No significance seen in the left
paw between the pre-CFA and post-CFA in either treatment group.
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DISCUSSION
The effects of the KD on inflammatory pain were analyzed using physiological
and behavioral techniques. The KD feeding promotes recovery after
inflammatory insult, however spontaneous pain did not illustrate a reduction in
nociceptive pain. Paw weights and volumes suggest that the paw is less swollen
and healing more quickly in rats fed a KD.

Physiological Effects
Ketone, Glucose and Body Weight
Our study found significant changes in the impact of KD on ketone levels
(fig.3A). This was expected, since the rats had been on the KD diet two to four
weeks. Glucose levels were not significantly altered (fig.3B). Masino and Ruskin
(2013) report a similar finding that rats had lowered blood glucose shortly after
starting the KD but at ten weeks there was no noticeable difference in blood
glucose levels between the KD and control. Previous studies indicate that there
are strong effects of the KD even when glucose is not significantly different
(Masino & Ruskin, 2013; Ruskin et al., 2013). Since the body weight was
consistent between the CD and KD (fig. 4), their paw displacement and paw
weight is also comparable to determine whether there was a difference of
inflammation due to diet.
Paw Weight and Paw Displacement
Paw weight illustrates a correlation between lowered paw weight and the
KD (fig. 5), which suggests that the KD reduces swelling in the right hind paw.
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Paw displacement almost reached significance (fig. 6) further suggesting that the
KD reduces swelling in the right hind paw. The body weight as mentioned
previously was not significantly different between the two diet groups, and thus
we can attribute this difference to paw volume and paw weight, and not to body
size. Paw size and paw weight depict the amount of swelling that occurred, the
trend towards lowered paw size and paw weight illustrates the KD may reduce
inflammation. These results are consistent with a previous study from our lab,
which found reduced inflammatory swelling and pain in juvenile and adult rats
on the KD. The specific study conducted by Ruskin et al. (2009) triggered
nociceptive pain and found a decrease in hind paw swelling in the KD compared
to the CD.
Our lab performed a similar study previously using CFA; only hind paw
swelling and plasma extravasation was analyzed in both juvenile and adult rats
(Masino & Ruskin, 2013). Masino and Ruskin (2013) found a larger significance
between the juvenile rats compared to the adult rats. The results from this
experiment may have not reached significance but based on this previous study
we cannot assume there was no effect.
Leukocyte Levels
Leukocyte levels were expected to be elevated in the KD right hind-paw
compared to the CD right hind-paw (fig. 7). A stronger anti-inflammatory
response is correlated with higher myeloperoxidase levels (Bradley et al. 1982).
The effect in myeloperoxidase levels between the groups because the CFA dose
might have been too high creating a ceiling effect that the KD could not rescue
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the inflammation. Trying a lower dose would help elucidate whether there is
stronger anti-inflammatory response in one diet group over the other.

Behavioral Effects
Tactile Sensitivity – Electronic Von Frey Probe
The responsiveness to tactile pressure was measured using an electronic
von Frey probe. There was a trend towards reduced nociception four hours post
CFA injection in the KD rats, as indicated by the very low pressure scores in
tactile sensitivity (fig. 8). Suggesting that the KD may help reduce pain after
inflammatory insult, but more testing would need to be performed. The trend
seen at four hours did not continue at 48-hours post CFA injection (fig. 8). It is
likely that the inflammatory pain is too strong and that a dietary treatment is not
able to cause a substantial difference in such a strong effect, thus we suggest
lowering the CFA dose in future experiments.
It is important to note some of the caveats with the electronic von Frey.
Prior to testing the tactile sensitivity with the electronic von Frey, we attempted
to quantify nociceptive pain using manual force of a von Frey hair. Six probes
with forces of 2.5, 5.93, 7.79, 21.92, 37, and 51.7g were applied to determine the
withdrawal reflex (Data not shown). Due to this sequential measure of tactile
sensitivity using a mechanical von Frey it is suspected that there was likely
increased sensitivity in both the manual and electronic von Frey measurements.
Increasing the amount of time between hind paw pokes may decrease the
variability and the risk of becoming sensitized. If we assume that this probing
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occurred regularly to the same degree and strength on each paw and animal,
another caveat that should be considered is the location of the pressure on the
paw. The location would alter the pressure; although the sensitivity was meant
to be at the same place each time there will be some variance. Furthermore,
another caveat is that depending on how the rat is positioned the pressure
needed to lift the paw varies and thus a lighter pressure may be recorded that is
not dependent on pain.
Many of the caveats listed above are problems inherent in manual and
electronic von Frey testing. However, in future studies we will likely remove
manual tactile sensitivity, as results were highly variable likely due to increased
sensitivity. The electronic von Frey seemed to give more consistent measures of
force.
Spontaneous Pain
Spontaneous pain was filmed and later analyzed on a five-point scale
depending on the movement of each hind paw. Within the KD there was a
significant difference before and after the CFA injection, similarly seen in the CD
before and after the CFA injection, exemplifying that the CFA produced a strong
inflammatory response (fig. 9). The lack in significance may result from the
difficulty of differentiating between the criteria between the scores in the middle.
The scoring criteria for 2, 3 and 4 on the spontaneous pain measure differentiated
between the areas in which pressure was placed on the paw. Distinguishing the
location of pressure may have caused the scoring to not strongly differentiate
between the scores for the different diet groups. The results had many zeroes and
overall the pain scores were relatively low, which caused the graphs to have their
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distribution close to the x-axis. Finding a clearer way to discern the spontaneous
pain could illustrate new significance in further studies. Furthermore we suggest
an earlier time point, as there were more significant trends seen closer to the CFA
injection. In the future a time point at roughly 6 hours post CFA injection should
be tried.

Effects of the KD on Inflammatory Pain
Rats were in ketosis, and any effects seen that differed between the KD
and CD rats could be attributed to the effects of the KD. Our results indicate that
the KD may alleviate pain, as there were significant changes indicating lowered
swelling from the right paw weight. Adding more rats to this study could alter
the trend to a significant difference between the KD and CD. Specifically, in paw
displacement and tactile sensitivity we saw a strong trend that may reach
significance with added rats.
Though the data on nociception is not quite as definitive, there is a trend
towards the KD decreasing nociception. Our lab aims to repeat this study by
adding more rats and altering some of the tests. As mentioned previously we
believe lowering the amount of CFA and pushing the spontaneous measurement
forward in the time should be tried in the future. It would be interesting to look
at juvenile rats, as Ruskin et al (2009) found more consistently significant
differences in pain in the juvenile KD compared to the adult KD.
It is likely that multiple mechanisms account for these changes in
nociception and inflammation, highlighted in the introduction. Our results more
strongly support a inflammatory mechanism as we see that swelling is reduced
41

through the paw weight and paw displacement than a nociceptive mechanism as
spontaneous pain had no change, and tactile only had a trend towards
significance.
Of the postulated mechanisms of the KD to influence pain (or seizures)
these data do not disprove most of them. For instance here we have not
measured GABA levels, vesicular glutamate uptake, mitochondrial profiles, etc.
We do disprove the glycolytic hypothesis, because of the KD effects that are
present with a lack of glucose. Our results do seem to support the antiinflammatory hypothesis regarding how the KD might be anti-convulsant or
anti-epileptic.
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CONCLUSION & FUTURE DIRECTIONS
The work included in this thesis demonstrates a trend that the KD may
lower inflammatory pain.
Our data illustrated that the KD rats had a lowered inflammatory pain at
four hours post inflammatory insult in the tactile sensitivity measure. There was
no reduction in nociceptive pain as there were no significant differences in the
spontaneous pain measure. Physiological measures indicated that rats were in
ketosis and appeared to have lowered paw volume and weight while body
weight did not alter suggesting that there may be a reduction in swelling in the
KD right hind paw. Increasing the number of rats could result in significance in
some of the tests that had close significance.
In an attempt to further discern whether the KD may aid in pain relief,
other models of pain should be studied. An arthritic model or an inflammatory
bowel disease model could be used to further study the effect of KD on
inflammatory diseases. Studying a different diet such as an MCT diet, which has
been shown to be easily metabolized and therapeutically effective in epilepsy
could be very beneficial to determine whether there are stronger effects than seen
in the KD. Another dietary regimen that should be pursued is calorie restriction,
which is anti-inflammatory (Shibolet et al., 2002).
The present results suggests that more data is needed to determine
whether the KD can help alleviate pain and reduce inflammation, however taken
together with previous studies it offers a promising avenue for pain alleviation
that should be pursued.
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Clinical work with the KD is still very minimal but could offers a wide set
of benefits as there are no side effects and very minimal cost. Alleviating pain
through an effective and non-pharmaceutical approach is extremely valuable for
millions of individuals suffering from either chronic pain or who would like to
use alternative medicine. Thus, focusing research on alleviating pain through a
dietary regimen or metabolic strategy could be extremely advantageous.
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